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odds ratio for exceeding the overall median was 1.0 (95% CI:
0.64–1.55). CONCLUSION: Pharmaceutical CUAs account for
almost half of all published CUAs. The quality of studies does
not appear to differ according to study sponsor. In the published
literature, the cost-effectiveness of pharmaceuticals is similar to
that of other interventions.
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It has been 40 years (1968) since Herbert Klarman and col-
leagues published their paper in Medical Care establishing that
the cost-effectiveness of kidney dialysis is $50,000/QALY. This
served as the basis for expanding the United States Medicare
program to provide universal coverage for end stage renal disease
and subsequently the basis upon which all new health technology
has been compared. This standard has not changed throughout
the health technology assessment community despite years of
inﬂation and structural changes in health care systems since this
time. This paper will ﬁrst re-examine Klarman’s work and
show how he quality-adjusted the life years in the wrong
direction—producing ill-year rather than healthy-year equivalent
years; therefore, he grossly underestimates the cost-effectiveness
ratio associated with kidney dialysis. The implication of this
mistake for health technology assessment and some suggestions
for new CE threshold standards will be discussed. Current con-
ditions in health technology assessment require that these new
standards be both dynamic—allowing for change over time—and
ﬂexible to allow adjustment based on mitigating factors like
budget impact. Several examples and evidence from Australia,
the UK and the United States will be presented to indicate how
these standards might be developed.
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OBJECTIVE: Quantify effect of alternative econometric models,
in estimating total direct medical expenditure in diabetes, arthri-
tis, cardiac diseases, asthma, hypertension, stroke, and emphy-
sema. METHODS: Data from the MEPS’s Household
Component (2004), a nationally representative survey of the U.S.
civilian noninstitutionalized population, was used. Accounting
for the survey’s clusters, strata and sampling weights; total direct
medical expenditure was estimated under 11 different economet-
ric models to assess their sensitivity to the zero mass, non-
negative values and skewed distribution. Models compared were,
OLS on raw-expenditure (OLSraw); OLS on log-expenditure
(LnHom) and homoskedastic-retransformation; OLS on log-
expenditure (LnHet) and heteroskedastic-retransformation;
GLM with log-link and Gamma-family (GLMGam); GLM with
log-link and Poisson-family (GLMPoi); Extended Estimating
Equations (EEE); and 2-part models of OLSraw (2POLSraw);
LnHom (2PLnHom); LnHet (2PLnHet); GLMGam
(2PGLMGam); and GLMPoi (2PGLMPoi). Incremental expen-
diture from the method of recycled predictions summed over
diseased population gave total expenditure. Box-Cox test con-
ﬁrmed log-link for GLM models while Modiﬁed Park’s test deter-
mined a distribution between the Poisson and the Gamma for the
family. LINK, RESET and Hosmer-Lemeshow test determined
model ﬁt, while COPAS test was employed for over-ﬁtting and
cross validation. Covariates included age, gender, race, ethnicity,
marital status, education, insurance status, and comorbidity.
RESULTS: Total expenditure in billions (b) of dollars, for diabe-
tes ranged from $48.5b(2POLSraw) to $127b(LnHet). Similarly,
expenditure of arthritis ranged from $73b(2POLSraw) to
$196b(LnHet); cardiac diseases ranged from $99.2b(2POLSraw)
to $194b(LnHet); asthma ranged from $27.8b(2POLSraw) to
$64.2b(GLMGam); emphysema ranged from $2.1b(2PLnHom)
to $18.4b(LnHet); hypertension ranged from
$69.9b(2POLSraw) to $241b(LnHet) and stroke ranged from
$13.1b(2PLnHom) to $39.3b(LnHet). LnHet model was consis-
tently associated with the highest total expenditure estimate,
while 2POLSraw model typically predicted the lowest estimate.
CONCLUSION: The strong inﬂuence of model choice on the
total medical expenditure estimate, underscores importance of
understanding the data generation procedure before selection of
the appropriate estimator.
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OBJECTIVES: A disease’s workplace impact on an employer is
often highly sought but rarely available information that an
employer can use to understand the value of a health intervention
and to inﬂuence health insurance coverage of that intervention.
This document presents a conceptual framework to analyze a
disease’s workplace impact on an employer. METHODS: The
conceptual framework presented here was developed on the basis
of a comprehensive literature review, extensive consultation
process, analytical mapping of concepts, objects, behaviors,
domains, functions, and relationships, as well as real case analy-
ses. RESULTS: A four-component conceptual framework of
workplace impact of a disease is proposed to guide researchers to
quantify disease-workplace-impact from an employer perspec-
tive. These four components are work interruption costs, work
care costs, worker turnover costs and productivity reduction
costs. The examples of work interruption costs include employer-
paid medical leaves, absence, short-term disability, and other
forms of work interruption resulted from a disease. The
examples of work care costs include disease related work adap-
tation costs, and a disease related insurance premium increase.
The examples of worker turnover costs include worker separa-
tion costs, new worker recruitment costs, and new worker train-
ing costs. The productivity reduction costs are mainly the costs of
productivity decrease resulted from presenteeism. Both predis-
posing factors and intervening factors of workplace impact are
discussed in this conceptual framework. Based on this conceptual
framework, we conducted a real world case analysis, which
suggests not only signiﬁcant workplace impact of a debilitating
disease, but also some methodological challenges in estimating
workplace impact of a disease from an employer’s perspective.
CONCLUSIONS: Our four-component conceptual framework
can guide researchers to quantify workplace impact of a disease
from an employer’s perspective. The real case analysis suggests a
debilitating disease not only affect patients, but also exert signiﬁ-
cant workplace impact on an employer.
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